SG11201808911SA - Trispecific and/or trivalent binding proteins - Google Patents

Trispecific and/or trivalent binding proteins

Info

Publication number
SG11201808911SA
SG11201808911SA SG11201808911SA SG11201808911SA SG11201808911SA SG 11201808911S A SG11201808911S A SG 11201808911SA SG 11201808911S A SG11201808911S A SG 11201808911SA SG 11201808911S A SG11201808911S A SG 11201808911SA SG 11201808911S A SG11201808911S A SG 11201808911SA
Authority
SG
Singapore
Prior art keywords
sanofi
international
frankfurt
main
binding proteins
Prior art date
Application number
SG11201808911SA
Other languages
English (en)
Inventor
Gary Nabel
Lan Wu
Zhi-Yong Yang
Edward Seung
Ronnie Wei
Jochen Beninga
Ercole Rao
Wulf Dirk Leuschner
Christian Beil
Christian Lange
Carsten Corvey
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58464471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201808911S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201808911SA publication Critical patent/SG11201808911SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201808911SA 2016-04-13 2017-04-13 Trispecific and/or trivalent binding proteins SG11201808911SA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662322036P 2016-04-13 2016-04-13
US201662331191P 2016-05-03 2016-05-03
US201662412187P 2016-10-24 2016-10-24
EP17305298 2017-03-17
PCT/US2017/027488 WO2017180913A2 (en) 2016-04-13 2017-04-13 Trispecific and/or trivalent binding proteins

Publications (1)

Publication Number Publication Date
SG11201808911SA true SG11201808911SA (en) 2018-11-29

Family

ID=58464471

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808911SA SG11201808911SA (en) 2016-04-13 2017-04-13 Trispecific and/or trivalent binding proteins

Country Status (23)

Country Link
US (2) US10882922B2 (es)
EP (1) EP3443006B1 (es)
JP (1) JP7195929B2 (es)
KR (1) KR20180134378A (es)
CN (1) CN109476732B (es)
AU (1) AU2017248671A1 (es)
BR (1) BR112018070998A2 (es)
CA (1) CA3020633A1 (es)
CL (1) CL2018002883A1 (es)
CO (1) CO2018012107A2 (es)
CR (1) CR20180539A (es)
DO (1) DOP2018000225A (es)
EA (1) EA201892312A1 (es)
IL (1) IL262241B2 (es)
MA (1) MA44670B1 (es)
MX (1) MX2018012566A (es)
PE (1) PE20190128A1 (es)
PH (1) PH12018502182A1 (es)
PT (1) PT3443006T (es)
SG (1) SG11201808911SA (es)
TW (1) TWI788286B (es)
UY (1) UY37206A (es)
WO (1) WO2017180913A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI803876B (zh) * 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017074878A1 (en) 2015-10-25 2017-05-04 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
RS64771B1 (sr) 2016-04-13 2023-11-30 Sanofi Sa Trispecifični i/ili trovalentni vezujući proteini
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
PT3443006T (pt) 2017-03-17 2023-10-26 Sanofi Sa Proteínas de ligação triespecíficas e/ou trivalentes
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
US11186649B2 (en) 2017-10-10 2021-11-30 Sanofi Anti-CD38 antibodies and methods of use
WO2019086500A2 (en) * 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Bispecific 2+1 contorsbodies
AU2018371114A1 (en) * 2017-11-21 2020-05-07 Innate Pharma Multispecific antigen binding proteins
CN109957026A (zh) * 2017-12-22 2019-07-02 成都恩沐生物科技有限公司 共价多特异性抗体
MX2020007444A (es) * 2018-01-12 2020-09-14 Genzyme Corp Metodos para la cuantificacion de polipeptidos.
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
CA3089230A1 (en) * 2018-03-02 2019-09-06 Cdr-Life Ag Trispecific antigen binding proteins
AU2019232762B2 (en) * 2018-03-08 2023-11-16 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
EP3765516A2 (en) * 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins
US10640576B2 (en) * 2018-04-10 2020-05-05 Y-Biologics Inc. Cell engaging binding molecules
MX2020011027A (es) * 2018-04-17 2021-01-15 Invenra Inc Constructos de anticuerpos biespecíficos trivalentes.
BR112021003023A2 (pt) * 2018-08-23 2021-05-11 Regeneron Pharmaceuticals, Inc. anticorpos anti-fc epsilon-r1 alfa (fcer1a), moléculas biespecíficas de ligação ao antígeno que ligam fcer1a e cd3, e usos dos mesmos
AU2019357467A1 (en) * 2018-10-09 2021-05-27 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
CN111153988B (zh) * 2018-11-08 2022-11-04 中国科学院上海巴斯德研究所 广谱抗肠道病毒d68型的中和性单克隆抗体
EP3674316A1 (en) 2018-12-24 2020-07-01 Sanofi Multispecific binding proteins with mutant fab domains
SG11202106393SA (en) 2018-12-24 2021-07-29 Sanofi Sa Pseudofab-based multispecific binding proteins
US11965030B2 (en) 2018-12-24 2024-04-23 Sanofi Multispecific binding proteins with mutant fab domains
WO2020172259A1 (en) * 2019-02-20 2020-08-27 Research Institute At Nationwide Children's Hospital Cancer-targeted, virus-encoded, regulatable t (catvert) or nk cell (catvern) linkers
TW202104274A (zh) 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
US11613576B2 (en) * 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
KR20210149141A (ko) 2019-04-09 2021-12-08 사노피 삼중특이적 결합 단백질, 이의 방법 및 용도
CN116987197A (zh) * 2019-06-20 2023-11-03 成都恩沐生物科技有限公司 共价多特异性抗体
EP3996747A4 (en) * 2019-07-11 2023-08-16 Tavotek Biotherapeutics (Hong Kong) Limited AGENTS INTERFERING WITH THYMUS TROMIC LYMPHOPOIETIN (TSLP) RECEPTOR SIGNALING
CN113166273A (zh) * 2019-07-25 2021-07-23 天境生物科技(上海)有限公司 具有il-7活性的双功能分子
WO2021080649A1 (en) 2019-10-25 2021-04-29 Sanofi Methods for analyzing chain mispairing in multispecific binding proteins
AU2020379735A1 (en) * 2019-11-05 2022-05-26 Regeneron Pharmaceuticals, Inc. N-terminal SCFV multispecific binding molecules
EP4110818A1 (en) 2020-02-26 2023-01-04 Biograph 55, Inc. C19 c38 bispecific antibodies
TW202146463A (zh) 2020-03-05 2021-12-16 法商賽諾菲公司 蛋白酶加工的分子
CN115380048A (zh) * 2020-03-30 2022-11-22 赛诺菲 分裂ch2结构域
KR20230016206A (ko) * 2020-06-23 2023-02-01 에프. 호프만-라 로슈 아게 Her2를 표적으로 하는 작용성 CD28 항원 결합 분자
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
KR20230070259A (ko) * 2020-09-18 2023-05-22 리제너론 파마슈티칼스 인코포레이티드 Cd38 및/또는 cd28에 결합하는 항원 결합 분자, 및 이의 용도
BR112023022584A2 (pt) 2021-05-27 2024-01-09 Sanofi Sa Variante fc com afinidade intensificada com receptores fc e estabilidade térmica melhorada
US20230227553A1 (en) * 2021-09-29 2023-07-20 Modex Therapeutics Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
WO2023060277A1 (en) * 2021-10-08 2023-04-13 Arbele Limited Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof
US20240059798A1 (en) * 2021-12-21 2024-02-22 Modex Therapeutics, Inc. Conditionally activated antigen binding polypeptide complexes and methods of use thereof
WO2023155845A1 (zh) * 2022-02-16 2023-08-24 上海优替济生生物医药有限公司 人源化抗cd28抗体及其与抗cd40的双特异性抗体
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
US20240132615A1 (en) 2022-05-05 2024-04-25 Ichnos Sciences SA CD3/BCMA/CD38 Trispecific Antibodies
WO2023227790A1 (en) 2022-05-27 2023-11-30 Sanofi Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering
WO2023246911A1 (zh) * 2022-06-24 2023-12-28 北京可瑞生物科技有限公司 基于t细胞受体的双特异性多肽分子及其用途
WO2024027828A1 (en) * 2022-08-05 2024-02-08 Chimagen Biosciences, Ltd Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
CN101684158A (zh) * 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
CN1294148C (zh) * 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
JP5091476B2 (ja) 2003-06-27 2012-12-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 均質な抗体溶液の生成のための疎水性相互作用クロマトグラフィーまたはヒンジ領域改変の使用
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) * 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AR072001A1 (es) 2008-06-03 2010-07-28 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
CN103403026B (zh) 2009-09-25 2016-05-11 美国政府(由卫生和人类服务部的部长所代表) Hiv-1中和抗体及其用途
JP6093696B2 (ja) 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
CN107903325B (zh) 2011-05-16 2021-10-29 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
CN103797029B (zh) 2011-05-17 2016-08-17 洛克菲勒大学 人类免疫缺陷病毒中和抗体及其使用方法
US9475862B2 (en) 2011-11-07 2016-10-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing GP41 antibodies and their use
CN108676091B (zh) 2011-12-08 2022-04-01 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
IN2015MN00139A (es) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
EP2948475A2 (en) * 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
EP3708584A1 (en) * 2013-02-26 2020-09-16 Roche Glycart AG Bispecific t cell activating antigen binding molecules
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
RU2015143833A (ru) 2013-03-15 2017-04-21 Эббви Инк. СВЯЗЫВАЮЩИЕ БЕЛКИ С ДВОЙНОЙ СПЕЦИФИЧНОСТЬЮ, НАПРАВЛЕННЫЕ ПРОТИВ TNFα
BR112016009919A2 (pt) 2013-11-04 2017-12-05 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento da mesma e método para produzir in vitro uma imunoglobulina hetero-dimérica ou fragmento da mesma
AP2016009475A0 (en) * 2014-03-28 2016-09-30 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
CA2996848C (en) 2014-09-04 2021-01-05 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion
AU2016210068B2 (en) 2015-01-23 2021-10-28 Sanofi Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
WO2016196740A1 (en) 2015-06-02 2016-12-08 The Rockefeller University Tri-specific antibodies for hiv therapy
CN108779161A (zh) 2015-09-22 2018-11-09 宾夕法尼亚大学董事会 重定向t细胞以治疗hiv感染的方法
WO2017074878A1 (en) 2015-10-25 2017-05-04 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
WO2017106346A2 (en) 2015-12-15 2017-06-22 Gilead Sciences, Inc. Human immunodeficiency virus neutralizing antibodies
US20230242876A1 (en) 2016-12-30 2023-08-03 Shanghai Sinobio Biotech Co., Ltd. Bifunctional molecule and use thereof
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
PT3443006T (pt) 2017-03-17 2023-10-26 Sanofi Sa Proteínas de ligação triespecíficas e/ou trivalentes
US11186649B2 (en) 2017-10-10 2021-11-30 Sanofi Anti-CD38 antibodies and methods of use
AU2019357467A1 (en) 2018-10-09 2021-05-27 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
CR20180539A (es) 2019-02-15
US10882922B2 (en) 2021-01-05
PT3443006T (pt) 2023-10-26
US11192960B2 (en) 2021-12-07
UY37206A (es) 2017-11-30
BR112018070998A2 (pt) 2019-02-26
CN109476732A (zh) 2019-03-15
EA201892312A1 (ru) 2019-04-30
CN109476732B (zh) 2024-03-22
JP2019522459A (ja) 2019-08-15
IL262241A (en) 2018-11-29
CA3020633A1 (en) 2017-10-19
DOP2018000225A (es) 2019-01-31
EP3443006A2 (en) 2019-02-20
WO2017180913A3 (en) 2018-02-08
PE20190128A1 (es) 2019-01-17
KR20180134378A (ko) 2018-12-18
US20210061925A1 (en) 2021-03-04
EP3443006B1 (en) 2023-08-02
CL2018002883A1 (es) 2019-01-18
IL262241B1 (en) 2024-01-01
MA44670A (fr) 2019-02-20
TWI788286B (zh) 2023-01-01
MX2018012566A (es) 2019-08-05
AU2017248671A1 (en) 2018-11-29
WO2017180913A9 (en) 2017-11-23
IL262241B2 (en) 2024-05-01
WO2017180913A2 (en) 2017-10-19
TW201803899A (zh) 2018-02-01
US20170320967A1 (en) 2017-11-09
PH12018502182A1 (en) 2019-11-04
MA44670B1 (fr) 2023-11-30
JP7195929B2 (ja) 2022-12-26
CO2018012107A2 (es) 2018-11-22

Similar Documents

Publication Publication Date Title
SG11201808911SA (en) Trispecific and/or trivalent binding proteins
SG11201810509PA (en) Anti-pd-l1 antibodies
SG11201901126UA (en) Combination therapy for cancer
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201903359RA (en) Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
SG11201808724SA (en) Anti-tim-3 antibodies and compositions
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201901899PA (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201909949XA (en) Targeted immunotolerance
SG11201811184UA (en) Lag -3 binding members
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201811643TA (en) Compounds and methods for modulating rna function
SG11201805493YA (en) Binding members with altered diversity scaffold domains
SG11201906341XA (en) Improved serum albumin binders
SG11201906264YA (en) Improved serum albumin binders
SG11201809620UA (en) The contorsbody - a single chain target binder
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201804443UA (en) Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201906392WA (en) Nucleoside-modified rna for inducing an immune response against zika virus